News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
274,004 Results
Type
Article (14267)
Company Profile (105)
Press Release (259624)
Multimedia
Podcasts (65)
Webinars (13)
Section
Business (88314)
Career Advice (465)
Deals (15399)
Drug Delivery (73)
Drug Development (36747)
Employer Resources (50)
FDA (6390)
Job Trends (6233)
News (150786)
Policy (14135)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (444)
Accelerated approval (13)
Adcomms (8)
Allergies (67)
Alliances (23319)
ALS (56)
Alzheimer's disease (479)
Antibody-drug conjugate (ADC) (99)
Approvals (6581)
Artificial intelligence (205)
Autoimmune disease (39)
Automation (12)
Bankruptcy (150)
Best Places to Work (4371)
BIOSECURE Act (9)
Biosimilars (118)
Biotechnology (40)
Bladder cancer (38)
Brain cancer (30)
Breast cancer (171)
Cancer (1317)
Cardiovascular disease (151)
Career advice (418)
Career pathing (13)
CAR-T (49)
CDC (6)
Cell therapy (152)
Cervical cancer (9)
Clinical research (32055)
Collaboration (725)
Compensation (325)
Complete response letters (33)
COVID-19 (779)
CRISPR (43)
C-suite (433)
Cystic fibrosis (58)
Data (1830)
Denatured (18)
Depression (45)
Diabetes (126)
Diagnostics (1385)
Digital health (8)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (113)
Drug pricing (114)
Drug shortages (12)
Duchenne muscular dystrophy (80)
Earnings (33489)
Editorial (20)
Employer branding (4)
Employer resources (45)
Events (39002)
Executive appointments (528)
FDA (7489)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (430)
Gene editing (70)
Generative AI (18)
Gene therapy (165)
GLP-1 (439)
Government (1405)
Grass and pollen (4)
Guidances (164)
Healthcare (3590)
HIV (11)
Huntington's disease (9)
IgA nephropathy (37)
Immunology and inflammation (68)
Immuno-oncology (14)
Indications (53)
Infectious disease (843)
Inflammatory bowel disease (73)
Inflation Reduction Act (7)
Influenza (24)
Intellectual property (113)
Interviews (60)
IPO (5919)
IRA (33)
Job creations (2055)
Job search strategy (374)
JPM (28)
Kidney cancer (9)
Labor market (28)
Layoffs (205)
Leadership (8)
Legal (3450)
Liver cancer (22)
Longevity (8)
Lung cancer (184)
Lymphoma (123)
Machine learning (13)
Management (17)
Manufacturing (412)
MASH (67)
Medical device (1307)
Medtech (1314)
Mergers & acquisitions (9900)
Metabolic disorders (434)
Multiple sclerosis (46)
NASH (14)
Neurodegenerative disease (82)
Neuropsychiatric disorders (38)
Neuroscience (903)
Neurotech (1)
NextGen: Class of 2026 (1592)
Non-profit (601)
Now hiring (17)
Obesity (227)
Opinion (141)
Ovarian cancer (39)
Pain (109)
Pancreatic cancer (51)
Parkinson's disease (80)
Partnered (11)
Patents (221)
Patient recruitment (116)
Peanut (12)
People (29751)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase 1 (8310)
Phase 2 (13526)
Phase 3 (12238)
Pipeline (1913)
Policy (135)
Postmarket research (1401)
Preclinical (3340)
Press Release (25)
Prostate cancer (84)
Psychedelics (16)
Radiopharmaceuticals (135)
Rare diseases (350)
Real estate (2666)
Recruiting (18)
Regulatory (10961)
Reports (15)
Research institute (575)
Resumes & cover letters (55)
Rett syndrome (5)
RNA editing (6)
RSV (20)
Schizophrenia (83)
Series A (80)
Series B (48)
Service/supplier (2)
Sickle cell disease (46)
Special edition (10)
Spinal muscular atrophy (81)
Sponsored (9)
Startups (1646)
State (2)
Stomach cancer (5)
Supply chain (49)
Tariffs (68)
The Weekly (45)
Vaccines (231)
Venture capital (32)
Weight loss (140)
Women's health (27)
Worklife (4)
Date
Last 7 days (178)
Last 30 days (679)
Last 365 days (10430)
2026 (955)
2025 (10735)
2024 (12510)
2023 (14262)
2022 (19577)
2021 (20099)
2020 (19057)
2019 (14909)
2018 (11725)
2017 (13893)
2016 (13134)
2015 (15477)
2014 (12421)
2013 (10594)
2012 (11398)
2011 (11926)
2010 (10891)
Location
Africa (318)
Alabama (19)
Alaska (1)
Arizona (77)
Arkansas (3)
Asia (20895)
Australia (2687)
California (3182)
Canada (1481)
China (550)
Colorado (143)
Connecticut (155)
Delaware (123)
Europe (40884)
Florida (601)
Georgia (63)
Hawaii (1)
Idaho (10)
Illinois (348)
India (44)
Indiana (240)
Iowa (2)
Japan (246)
Kansas (77)
Kentucky (20)
Louisiana (4)
Maine (2)
Maryland (421)
Massachusetts (2586)
Michigan (46)
Minnesota (168)
Mississippi (1)
Missouri (33)
Montana (8)
Nebraska (7)
Nevada (16)
New Hampshire (8)
New Jersey (1396)
New Mexico (7)
New York (907)
North Carolina (619)
North Dakota (2)
Northern California (1450)
Ohio (80)
Oklahoma (5)
Oregon (18)
Pennsylvania (715)
Puerto Rico (12)
Rhode Island (17)
South America (508)
South Carolina (10)
Southern California (1389)
Tennessee (53)
Texas (454)
United States (12703)
Utah (59)
Virginia (160)
Washington D.C. (42)
Washington State (223)
West Virginia (1)
Wisconsin (37)
Wyoming (1)
274,004 Results for "serenity pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes
October 15, 2025
·
8 min read
Press Releases
BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia
September 10, 2025
·
18 min read
Press Releases
BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
August 20, 2025
·
11 min read
Press Releases
UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®
August 28, 2025
·
19 min read
Press Releases
BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025
August 26, 2025
·
10 min read
Press Releases
BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
August 4, 2025
·
9 min read
Press Releases
BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
July 2, 2025
·
11 min read
BioMidwest
Beltone Unveils a New Generation of Hearing Solutions with Beltone Serene
Beltone, named one of America’s Best Retailers and Customer Service for Hearing Care by Newsweek, announced its latest innovation in hearing care – the new Beltone Serene™ hearing aid.
September 28, 2023
·
4 min read
Press Releases
BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
May 27, 2025
·
11 min read
Press Releases
BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
March 10, 2025
·
12 min read
1 of 27,401
Next
